Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
7 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Characterization of PF-6142, a Novel, Non-Catecholamine Dopamine Receptor D1 Agonist, in Murine and Nonhuman Primate Models of Dopaminergic Activation.
Front Pharmacol. 2020 Jul 7;11:1005. doi: 10.3389/fphar.2020.01005. eCollection 2020.
Front Pharmacol. 2020.
PMID: 32733245
Free PMC article.
Discovery and Lead Optimization of Atropisomer D1 Agonists with Reduced Desensitization.
Davoren JE, Nason D, Coe J, Dlugolenski K, Helal C, Harris AR, LaChapelle E, Liang S, Liu Y, O'Connor R, Orozco CC, Rai BK, Salafia M, Samas B, Xu W, Kozak R, Gray D.
Davoren JE, et al. Among authors: dlugolenski k.
J Med Chem. 2018 Dec 27;61(24):11384-11397. doi: 10.1021/acs.jmedchem.8b01622. Epub 2018 Dec 11.
J Med Chem. 2018.
PMID: 30431269
Item in Clipboard
Design and optimization of selective azaindole amide M1 positive allosteric modulators.
Davoren JE, O'Neil SV, Anderson DP, Brodney MA, Chenard L, Dlugolenski K, Edgerton JR, Green M, Garnsey M, Grimwood S, Harris AR, Kauffman GW, LaChapelle E, Lazzaro JT, Lee CW, Lotarski SM, Nason DM, Obach RS, Reinhart V, Salomon-Ferrer R, Steyn SJ, Webb D, Yan J, Zhang L.
Davoren JE, et al. Among authors: dlugolenski k.
Bioorg Med Chem Lett. 2016 Jan 15;26(2):650-655. doi: 10.1016/j.bmcl.2015.11.053. Epub 2015 Nov 17.
Bioorg Med Chem Lett. 2016.
PMID: 26631313
Item in Clipboard
Discovery of the Potent and Selective M1 PAM-Agonist N-[(3R,4S)-3-Hydroxytetrahydro-2H-pyran-4-yl]-5-methyl-4-[4-(1,3-thiazol-4-yl)benzyl]pyridine-2-carboxamide (PF-06767832): Evaluation of Efficacy and Cholinergic Side Effects.
Davoren JE, Lee CW, Garnsey M, Brodney MA, Cordes J, Dlugolenski K, Edgerton JR, Harris AR, Helal CJ, Jenkinson S, Kauffman GW, Kenakin TP, Lazzaro JT, Lotarski SM, Mao Y, Nason DM, Northcott C, Nottebaum L, O'Neil SV, Pettersen B, Popiolek M, Reinhart V, Salomon-Ferrer R, Steyn SJ, Webb D, Zhang L, Grimwood S.
Davoren JE, et al. Among authors: dlugolenski k.
J Med Chem. 2016 Jul 14;59(13):6313-28. doi: 10.1021/acs.jmedchem.6b00544. Epub 2016 Jul 1.
J Med Chem. 2016.
PMID: 27275946
Item in Clipboard
α5 nAChR modulation of the prefrontal cortex makes attention resilient.
Howe WM, Brooks JL, Tierney PL, Pang J, Rossi A, Young D, Dlugolenski K, Guillmette E, Roy M, Hales K, Kozak R.
Howe WM, et al. Among authors: dlugolenski k.
Brain Struct Funct. 2018 Mar;223(2):1035-1047. doi: 10.1007/s00429-017-1601-1. Epub 2018 Jan 3.
Brain Struct Funct. 2018.
PMID: 29299690
Item in Clipboard
Dopamine D3/D2 Receptor Antagonist PF-4363467 Attenuates Opioid Drug-Seeking Behavior without Concomitant D2 Side Effects.
Wager TT, Chappie T, Horton D, Chandrasekaran RY, Samas B, Dunn-Sims ER, Hsu C, Nawreen N, Vanase-Frawley MA, O'Connor RE, Schmidt CJ, Dlugolenski K, Stratman NC, Majchrzak MJ, Kormos BL, Nguyen DP, Sawant-Basak A, Mead AN.
Wager TT, et al. Among authors: dlugolenski k.
ACS Chem Neurosci. 2017 Jan 18;8(1):165-177. doi: 10.1021/acschemneuro.6b00297. Epub 2016 Oct 21.
ACS Chem Neurosci. 2017.
PMID: 27715007
Item in Clipboard
Pharmacological disruption of mouse social approach behavior: relevance to negative symptoms of schizophrenia.
Hanks AN, Dlugolenski K, Hughes ZA, Seymour PA, Majchrzak MJ.
Hanks AN, et al. Among authors: dlugolenski k.
Behav Brain Res. 2013 Sep 1;252:405-14. doi: 10.1016/j.bbr.2013.06.017. Epub 2013 Jun 25.
Behav Brain Res. 2013.
PMID: 23806621
Item in Clipboard
Cite
Cite